These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37029329)

  • 1. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA; Shatsky RA; Schwab RB; Wallace AM; ; Wolf DM; Hirst GL; Brown-Swigart L; Esserman LJ; van 't Veer LJ; Ghia EM; Yau C; Kipps TJ
    Breast Cancer Res Treat; 2023 Jun; 199(2):281-291. PubMed ID: 37029329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
    JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
    Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
    Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    ; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
    JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
    JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C; Osdoit M; van der Noordaa M; Shad S; Wei J; de Croze D; Hamy AS; Laé M; Reyal F; Sonke GS; Steenbruggen TG; van Seijen M; Wesseling J; Martín M; Del Monte-Millán M; López-Tarruella S; ; Boughey JC; Goetz MP; Hoskin T; Gould R; Valero V; Edge SB; Abraham JE; Bartlett JMS; Caldas C; Dunn J; Earl H; Hayward L; Hiller L; Provenzano E; Sammut SJ; Thomas JS; Cameron D; Graham A; Hall P; Mackintosh L; Fan F; Godwin AK; Schwensen K; Sharma P; DeMichele AM; Cole K; Pusztai L; Kim MO; van 't Veer LJ; Esserman LJ; Symmans WF
    Lancet Oncol; 2022 Jan; 23(1):149-160. PubMed ID: 34902335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
    Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
    Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the Ror family receptors in Wnt5a signaling.
    Kamizaki K; Minami Y; Nishita M
    In Vitro Cell Dev Biol Anim; 2024 May; 60(5):489-501. PubMed ID: 38587578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
    J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M; Yau C; Symmans WF; Boughey JC; Ewing CA; Balassanian R; Chen YY; Krings G; Wallace AM; Zare S; Fadare O; Lancaster R; Wei S; Godellas CV; Tang P; Tuttle TM; Klein M; Sahoo S; Hieken TJ; Carter JM; Chen B; Ahrendt G; Tchou J; Feldman M; Tousimis E; Zeck J; Jaskowiak N; Sattar H; Naik AM; Lee MC; Rosa M; Khazai L; Rendi MH; Lang JE; Lu J; Tawfik O; Asare SM; Esserman LJ; Mukhtar RA
    JAMA Surg; 2022 Nov; 157(11):1034-1041. PubMed ID: 36069821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex.
    Endo M; Doi R; Nishita M; Minami Y
    J Cell Sci; 2012 Apr; 125(Pt 8):2017-29. PubMed ID: 22328498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Receptor Tyrosine Kinase-Like Orphan Receptors in Intestinal-Type Gastric Cancer.
    Nema R; Patel P; Kumar A
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2125-2134. PubMed ID: 34319035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target.
    Liu D; Gunther K; Enriquez LA; Daniels B; O'Mara TA; Tang K; Spurdle AB; Ford CE
    Sci Rep; 2020 Aug; 10(1):13906. PubMed ID: 32807831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.
    Saleh RR; Antrás JF; Peinado P; Pérez-Segura P; Pandiella A; Amir E; Ocaña A
    Cancer Treat Rev; 2019 Jul; 77():11-19. PubMed ID: 31174180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential role of Wnt5a-Ror1/Ror2 signaling in metanephric mesenchyme and ureteric bud formation.
    Qi X; Okinaka Y; Nishita M; Minami Y
    Genes Cells; 2016 Apr; 21(4):325-34. PubMed ID: 26840931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
    Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
    Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROR1 and ROR2 expression in pancreatic cancer.
    Liu D; Sharbeen G; Phillips P; ; Ford CE
    BMC Cancer; 2021 Nov; 21(1):1199. PubMed ID: 34763666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.
    Raivola J; Dini A; Salokas K; Karvonen H; Niininen W; Piki E; Varjosalo M; Ungureanu D
    Cell Mol Life Sci; 2022 May; 79(5):276. PubMed ID: 35504983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.